Europe Cancer Metabolism Based Therapeutics Market Size, Share & Growth Trend Analysis Report (2026 - 2035)

Market Outlook

The Europe cancer metabolism based therapeutics market, valued at USD 0.82 billion in 2025, is projected to reach USD 1.12 billion in 2026 and USD 8.54 billion by 2035, with a CAGR of 25.3% during the forecast period 2026 to 2035.

To learn more about this report, request a free sample copy

Market Report: Key Takeaways

Market Size and Trends

• In terms of type of modality, small molecules are expected to account for the largest market share in 2026; this trend is unlikely to change in the future.
• With respect to route of administration, oral route (close to 85%) is expected to dominate the market in 2035.
• Based on target disease indication, in 2026, breast cancer is expected to account for the largest Europe cancer metabolism based therapeutics market share.

Key Market Statistics

• Market Size in 2026: $1.12 billion
• Estimated Market Size in 2035: $8.54 billion
• CAGR (Till 2035): 25.3%

Market Introduction

Cancer cells undergo profound metabolic reprogramming to sustain uncontrolled proliferation, evade immune surveillance, and survive under nutrient- and oxygen-deprived conditions. This metabolic plasticity, often characterized by altered glucose, amino acid, and lipid metabolism, has emerged as a defining hallmark of cancer and an attractive therapeutic target. Advances in cancer biology have led to the development of metabolism based therapeutics that selectively disrupt these metabolic dependencies, offering a novel treatment strategy that complements conventional chemotherapy, targeted therapy, and cancer immunotherapy. As the understanding of tumor metabolism continues to evolve, the field is witnessing increasing research activity focused on identifying new metabolic targets and developing precision therapeutics for a broad range of malignancies.

In Europe, the oncology market is underpinned by a substantial cancer burden and a sustained transition toward precision medicine. The World Health Organization (WHO) reports that while Europe comprises approximately 9% of the global population, it accounts for 23.4% of diagnoses and 20.3% of cancer-related deaths. This disproportionate disease burden is driving increased adoption of targeted therapies designed to address molecularly defined patient subgroups.

The European cancer metabolism based therapeutics market is also being strengthened by recent regulatory progress in metabolism-linked targeted therapies. For example, Voranigo (vorasidenib) received European marketing authorization in September 2025 for the treatment of glioma; the drug specifically targets mutant IDH enzymes that drive aberrant metabolic pathways. This approval exemplifies how metabolic vulnerabilities, such as IDH mutations and consequent oncometabolite production, are being translated into approved oncology therapies in Europe.

Going forward, the Europe market is expected to benefit from expanding biomarker testing, stronger clinical trial activity, and increasing regulatory focus on personalized cancer treatment. The EMA notes that personalized oncology focuses on targeting specific molecular alterations that drive cancer progression, enabling treatment selection based on each tumor's molecular and genetic profile. As European healthcare systems continue to adopt precision-led oncology models, cancer metabolism based therapeutics are likely to gain relevance across both hematologic malignancies and solid tumors where defined metabolic targets can guide therapy selection.

Market Segmentation

Based on the research, we have segmented the Europe Cancer Metabolism Based Therapeutics Market Report into type of modality, route of administration, target disease indication and sales forecast of therapies.

By Type of Modality

• Small Molecules
• Biologics

By Route of Administration

• Oral
• Intravenous
• Intramuscular

By Target Disease Indication

• Breast Cancer
• Non-small Cell Lung Cancer
• Acute Myeloid Leukemia
• Brain Cancer
• Cholangiocarcinoma
• Bile Duct Cancer
• Myelodysplastic Syndromes
• Malignant Mesothelioma
• Soft Tissue Sarcoma
• Hepatocellular Carcinoma
• Pancreatic Cancer

By Sales Forecast of Therapies

• Daraxonrasib
• Gedatolisib
• Olomorasib
• Inavolisib
• Vorasidenib
• STX-478
• AZD 5363
• AG-120
• Selpercatinib
• ADI-PEG 20
• Augtyro
• Taletrectinib
• Piqray
• TAS-120

Key Market Insights

What Factors are Driving Increased Adoption of Cancer Metabolism Based Therapeutics in Europe?

• Expansion of Precision Oncology and Biomarker Testing: Cancer metabolism based therapeutics depend heavily on identifying patients with specific molecular or metabolic alterations. Europe's growing focus on personalized oncology is therefore supporting adoption. For instance, in March 2026, EPPermed released a white paper on advancing precision oncology treatment and biomarker testing across Europe, highlighting practical implementation tools and case studies to improve patient access to targeted therapies.
• Strong Clinical Evidence Supporting Metabolism-Targeted Approaches: Positive clinical trial outcomes are improving physician confidence in cancer metabolism based therapeutics. For instance, in the pivotal INDIGO study, vorasidenib significantly improved progression-free survival and delayed time to next intervention in patients with Grade 2 IDH-mutant glioma. Such clinical evidence strengthens the case for metabolism based therapeutics, particularly in biomarker-defined cancers where metabolic mutations are actionable.

What are the Key Trends in the Europe Cancer Metabolism Based Therapeutics Market?

• Growing Use of Liquid Biopsy and Genomic Testing to Accelerate Therapy Selection: Wider use of molecular diagnostics is supporting faster identification of patients eligible for targeted therapies. For example, in May 2025, NHS England announced the rollout of a liquid biopsy test for lung and breast cancer patients to speed access to targeted therapy and help some patients avoid further tests or chemotherapy.
• Shift From Broad Oncology Treatment to Metabolism-Targeted Precision Therapy: Europe is witnessing stronger adoption of therapies that target specific metabolic alterations rather than broadly attacking rapidly dividing cancer cells. IDH-targeted therapies are a major example, as mutant IDH enzymes create abnormal metabolic activity that supports tumor growth. EMA-authorized products such as Tibsovo (ivosidenib) for IDH1-mutated AML and cholangiocarcinoma, and Voranigo (vorasidenib) for IDH-mutant glioma, show that metabolism-linked targets are becoming clinically validated in Europe.

Recent Developments in Europe Cancer Metabolism Based Therapeutics Market

• In June 2026, Step Pharma advanced dencatistat into a Phase 2 clinical trial for essential thrombocythemia. Dencatistat is a first-in-class, highly selective oral CTPS1 inhibitor, and the Phase 2 VECTRA trial will evaluate safety, tolerability, and efficacy in up to 50 high-risk patients across sites in the US, the EU and the UK, strengthening Europe's clinical pipeline in metabolism-directed hematology and oncology.
• In May 2026, Servier presented extended Phase 3 INDIGO follow-up data for VORANIGO® (vorasidenib) at ASCO 2026. The updated analysis showed median progression-free survival of 44.1 months in patients with Grade 2 IDH-mutant glioma, further strengthening the clinical evidence supporting IDH inhibition in European neuro-oncology practice.
• In February 2026, Step Pharma secured a EUR 2.5 million European Innovation Council grant, with potential equity investment of up to EUR 10 million, to advance dencatistat in CTPS2-null gynecologic tumors. The funding supports expansion cohorts in ovarian and endometrial cancers, where CTPS2 loss creates a synthetic lethal dependency on CTPS1 inhibition.

Industry Experts on Europe Cancer Metabolism Based Therapeutics Market

The market for cancer metabolism based therapies in Europe is poised for transformative growth, driven by continued progress in specialized targeted treatments.

Highlighting this trend, Jennifer Simpson (Chief Executive Officer, Panbela Therapeutics) stated that "We believe that the addition of ivospemin, or SBP-101, to the standard-of-care regimen of gemcitabine and nab-paclitaxel has the potential to significantly improve outcomes for patients with metastatic pancreatic ductal adenocarcinoma, beyond the incremental benefit observed with the recently approved therapy. The early indications from the ASPIRE trial support this belief, and we remain committed to advancing this important study"

The Europe Cancer Metabolism Based Therapeutics Market report includes detailed discussions of multiple stakeholders in this domain, which have influenced the opinions and insights presented in this study. The market report includes transcripts of the following third-party discussions:

• President and Chief Executive Officer, Mid-sized Company, US
• President and Chief Executive Officer, Mid-sized Company, US
• Chief Executive Officer, Mid-sized Company, US
• Chief Financial Officer, Mid-sized Company, US
• Associate Professor, Very Large Company, US
• Medical Oncologist, Very Large Company, US
• Associate Professor, Large Company, Germany
• Former Vice President, Head of Research and Translational Sciences, Large Company, US
• Postdoctoral Researcher, Very Large Company, US
• Consultant Dietitian

Market Share Insights

Which Type of Modality Accounts for the Largest Market Share?

• Based on the Europe cancer metabolism based therapeutics market analysis, the small molecules segment is likely to occupy the highest market share in the current year due to their proven clinical efficacy, ease of oral administration, lower production costs, and well-established safety profiles. Moreover, small-molecule inhibitors effectively target intracellular metabolic enzymes and pathways such as mutated IDH1/2 in gliomas and AML that are often inaccessible to larger biologics.
• The biologics segment is likely to witness a higher CAGR in the future. This is primarily owing to their emerging role in offering high specificity, dual mechanisms of action, and innovative therapeutic potential that complement existing treatments.

Which Route of Administration Accounts for the Largest Europe Cancer Metabolism Based Therapeutics Market Share?

• In 2035, the oral route segment is likely to occupy the highest (~85%) market share. Further, this segment is also likely to record significant growth rate during the forecast period. This can be attributed to several advantages, such as patient convenience, cost efficiency, and manufacturing scalability. Oral formulations are also widely preferred for chronic therapy, self-administration, and large-volume commercial supply, which supports sustained demand over the forecast period.
• The intramuscular segment is likely to witness a higher CAGR in the future, driven by the increasing development of injectable biologics and cell-based therapies that require rapid systemic absorption and reliable bioavailability.

Among the Target Disease Indications, Which Segment Holds the Highest Share in the Europe Cancer Metabolism Based Therapeutics Market?

• Currently, the breast cancer segment occupies a higher Europe cancer metabolism based therapeutics market share. This is primarily due to the high disease burden of breast cancer, extensive research on tumor metabolic reprogramming, and the increasing clinical evaluation of metabolism-targeted therapies in combination with endocrine therapy, chemotherapy, and immunotherapy.
• The non-small cell lung cancer segment is likely to grow at a higher CAGR during the forecast period. This is primarily because NSCLC represents the dominant subtype of lung cancer and remains associated with high unmet clinical need, late-stage diagnosis, treatment resistance, and significant mortality burden across Europe. For instance, the European Commission's latest EU cancer data, published in December 2025, reported that lung cancer accounted for 19.7% of all cancer deaths in the EU, making it the leading cause of cancer mortality.

Scope of Europe Cancer Metabolism Based Therapeutics Market Report